Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 3.0 | 4.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 2.35 | 1.88 |
NAV | ₹16.25 | ₹40.01 |
Fund Started | 18 Oct 2021 | 25 Jun 2018 |
Fund Size | ₹235.68 Cr | ₹6103.96 Cr |
Exit Load | Exit load of 0.50%, if redeemed within 3 months. | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | -1.32% | 4.88% |
3 Year | 21.46% | 28.57% |
5 Year | - | 21.25% |
1 Year
3 Year
5 Year
Equity | 98.71% | 95.89% |
Cash | 1.29% | 4.11% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 10.93% |
Divi's Laboratories Ltd. | 8.68% |
Max Healthcare Institute Ltd. | 6.12% |
Apollo Hospitals Enterprise Ltd. | 5.66% |
Cohance Lifesciences Ltd. | 4.66% |
Torrent Pharmaceuticals Ltd. | 4.58% |
Aurobindo Pharma Ltd. | 3.66% |
Fortis Healthcare Ltd. | 3.51% |
Lupin Ltd. | 3.46% |
Aster DM Healthcare Ltd. | 3.19% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 11.69% |
Dr. Reddy's Laboratories Ltd. | 8.85% |
Divi's Laboratories Ltd. | 8.13% |
Cipla Ltd. | 7.54% |
Aurobindo Pharma Ltd. | 5.71% |
Lupin Ltd. | 5.11% |
Mankind Pharma Ltd. | 3.88% |
Alkem Laboratories Ltd. | 3.83% |
Biocon Ltd. | 3.64% |
Gland Pharma Ltd. | 3.20% |
Name | Dhimant Shah | Dharmesh Kakkad |
Start Date | 29 May 2023 | 16 Jan 2021 |
Name
Start Date
Description | The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 18 Oct 2021 | 25 Jun 2018 |
Description
Launch Date